CN111772050A - 大鼠高尿酸血症模型饲料及其制备方法和应用 - Google Patents
大鼠高尿酸血症模型饲料及其制备方法和应用 Download PDFInfo
- Publication number
- CN111772050A CN111772050A CN202010885542.7A CN202010885542A CN111772050A CN 111772050 A CN111772050 A CN 111772050A CN 202010885542 A CN202010885542 A CN 202010885542A CN 111772050 A CN111772050 A CN 111772050A
- Authority
- CN
- China
- Prior art keywords
- rat
- feed
- hyperuricemia model
- rat hyperuricemia
- model feed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 238000001816 cooling Methods 0.000 claims abstract description 11
- 239000008188 pellet Substances 0.000 claims abstract description 10
- 238000001035 drying Methods 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 229930024421 Adenine Natural products 0.000 claims abstract description 7
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960000643 adenine Drugs 0.000 claims abstract description 7
- 239000002285 corn oil Substances 0.000 claims abstract description 7
- 235000005687 corn oil Nutrition 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000005303 weighing Methods 0.000 claims abstract description 4
- 241000700159 Rattus Species 0.000 claims description 68
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 15
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 13
- 229940116269 uric acid Drugs 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 8
- 239000003921 oil Substances 0.000 claims description 8
- 235000019198 oils Nutrition 0.000 claims description 8
- 241000700157 Rattus norvegicus Species 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 239000011812 mixed powder Substances 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 229920002261 Corn starch Polymers 0.000 claims description 4
- 239000004470 DL Methionine Substances 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 229960004874 choline bitartrate Drugs 0.000 claims description 4
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 claims description 4
- 239000008120 corn starch Substances 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 235000006109 methionine Nutrition 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 3
- 239000005018 casein Substances 0.000 claims description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 3
- 235000021240 caseins Nutrition 0.000 claims description 3
- 238000010276 construction Methods 0.000 claims description 3
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 abstract description 17
- 241001465754 Metazoa Species 0.000 abstract description 6
- 241000282414 Homo sapiens Species 0.000 abstract description 5
- 238000010171 animal model Methods 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 238000003304 gavage Methods 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000008506 pathogenesis Effects 0.000 abstract description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 201000005569 Gout Diseases 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 102000011632 Caseins Human genes 0.000 description 3
- 108010076119 Caseins Proteins 0.000 description 3
- 206010046337 Urate nephropathy Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- -1 compound vitamin Chemical class 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 206010018641 Gouty tophus Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 229950000193 oteracil Drugs 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/50—Feeding-stuffs specially adapted for particular animals for rodents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/02—Breeding vertebrates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/153—Nucleic acids; Hydrolysis products or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/26—Compounds containing phosphorus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/10—Shaping or working-up of animal feeding-stuffs by agglomeration; by granulation, e.g. making powders
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Animal Husbandry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Environmental Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Birds (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明属于本发明属于实验动物技术领域,具体涉及大鼠高尿酸血症模型饲料的制备方法,精确称取基础饲料、0.15%‑0.2%质量比的腺嘌呤进行混合,加入玉米油进行搅拌,在冷却桶中进行降温处理后,加入水分搅拌混合,通过制粒机进行制粒,获得软颗粒饲料;进行低温烘干水分,获得大鼠高尿酸血症模型饲料。本发明还提供了大鼠高尿酸血症模型饲料及其应用。本发明提供的大鼠高尿酸血症模型不造成肾脏严重器质性损伤,成功复制与人类高尿酸血症病发病机制相类似的动物模型,为后续的药物观察治疗动物实验研究提供了基础。本发明仅通过单纯的饲料喂养大鼠,无需采用灌胃手段,符合动物伦理,即可获得大鼠高尿酸血症模型,从而为人类相关疾病研究提供理论基础。
Description
技术领域
本发明属于实验动物技术领域,具体涉及大鼠高尿酸血症模型饲料及其制备方法和应用。
背景技术
目前人们对尿酸盐在体内的代谢已经有了较全面的认识,在痛风的遗传学研究方面也取得了一些进展。生物体血尿酸水平主要受肾转运系统的调节。痛风是由于嘌呤代谢紊乱,导致血尿酸增高和\或肾脏排泄尿酸减少,从而引起尿酸盐在组织沉积的疾病,其自然病程分为无症状高尿酸血症、急性痛风性关节炎、间歇期痛风、慢性痛风石性痛风四个阶段,偶尔也会出现痛风性肾病。约10%的高尿酸血症患者会自然发展为痛风。
目前用于高尿酸血症治疗研究的动物模型中,氧嗪酸钾作为抑制尿酸产生的化学诱导剂建立的高尿酸血症模型,以其灵敏简便、重复性好,在国际上被普遍采用。此外,也有研究者用尿酸和酵母膏成功诱导动物高尿酸血症模型的报道。高尿酸血症引起的肾实质损害有两种类型一种称为尿酸盐肾病,第二种是尿酸性肾病。腺嘌呤在剂量为300ppm灌胃给药时,大鼠肾脏损害十分严重,整个肾脏呈白色,重量约为正常肾脏的一倍大小,肾组织结构完全破坏,根本无逆转的可能,无法观察药物疗。
发明内容
针对上述现有技术的不足,本发明提供了大鼠高尿酸血症模型饲料的制备方法,目的是为了解决现有技术中腺嘌呤在剂量为300ppm灌胃给药时,大鼠肾脏损害十分严重,整个肾脏呈白色,重量约为正常肾脏的一倍大小,肾组织结构完全破坏,根本无逆转的可能,无法观察药物疗的技术问题。本发明还提供了大鼠高尿酸血症模型饲料及其应用。
本发明提供的大鼠高尿酸血症模型饲料的制备方法,具体技术方案如下:
大鼠高尿酸血症模型饲料的制备方法,包括如下步骤:
S1,精确称取基础饲料、0.15%-0.2%质量比的腺嘌呤进行混合,获得混合粉料;
S2,步骤S1中的混合粉料加入玉米油进行搅拌,获得油料混合物;
S3,步骤S2中的油料混合物放置在冷却桶中进行降温处理后,加入水分搅拌混合,通过制粒机进行制粒,获得软颗粒饲料;
S4,将步骤S3中的软颗粒饲料进行低温烘干水分,获得大鼠高尿酸血症模型饲料,所述大鼠高尿酸血症模型饲料中钙的含量为0.6%,磷的含量为0.9%。
在某些实施方式中,步骤S1中,所述基础饲料按质量百分比计包括19.57%酪蛋白、0.29%DL-蛋氨酸、14.68%玉米淀粉、48.93%蔗糖、4.89%纤维素、3.42%复合矿物质、0.27%磷酸氢钙、1.88%磷酸二氢钾、0.98%复合维生素和0.20%酒石酸氢胆碱。
在某些实施方式中,步骤S2中,按质量比计,所述玉米油为4.89%。
在某些实施方式中,步骤S3中,所述油料混合物放置在冷却桶中降至室温,所述软颗粒饲料的粒径10-15mm。
在某些实施方式中,步骤S4中,所述烘干的温度为26摄氏度,时间为48小时。
本发明还提供了根据上述方法制备的大鼠高尿酸血症模型饲料。
本发明提供了大鼠高尿酸血症模型饲料的应用,连续给wistar大鼠或SD大鼠饲喂上述的大鼠高尿酸血症模型饲料14天-21天,自由饮水,饲喂后的大鼠血尿酸为正常饮食的大鼠血尿酸的3-4倍,即大鼠高尿酸血症模型构建完成。
本发明具有以下有益效果:本发明提供的方法制备的大鼠高尿酸血症模型饲料喂养大鼠16-21天,可以发现大鼠的尿酸明显升高并出现慢性肾功能衰竭,不造成肾脏严重器质性损伤,成功复制与人类高尿酸血症病发病机制相类似的动物模型,为后续的药物观察治疗动物实验研究提供了基础。此外,本发明仅通过单纯的饲料喂养大鼠,无需采用灌胃手段,符合动物伦理,即可获得大鼠高尿酸血症模型,模拟人类高尿酸血症的各种症状,从而为人类相关疾病研究提供理论基础。
附图说明
图1是本发明提供的大鼠高尿酸血症模型饲料的制备方法的流程图;
图2是实施例1对照组与实施例组的大鼠血液指标和尿液指标的对比图;
图3是实施例1对照组与实施例组的大鼠总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)的对比图;
图4是实施例1对照组与实施例组的大鼠肝肾质量及系数对比图。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚明白,以下结合具体实施例,并参照附图,对本发明进一步详细说明。
实施例1
本实施例提供的大鼠高尿酸血症模型饲料的制备方法,具体技术方案如下:
如图1所示,大鼠高尿酸血症模型饲料的制备方法,包括如下步骤:
S1,精确称如表1所示的原料,按质量比计,19.57%酪蛋白、0.29%DL-蛋氨酸、14.68%玉米淀粉、48.93%蔗糖、4.89%纤维素、3.42%复合矿物质、0.27%磷酸氢钙、1.88%磷酸二氢钾、0.98%复合维生素、0.20%酒石酸氢胆碱和0.15%-0.2%质量比的腺嘌呤进行混合,获得混合粉料;
S2,步骤S1中的混合粉料加入质量比4.89%的玉米油进行搅拌,获得油料混合物;
S3,步骤S2中的油料混合物放置在冷却桶中进行降温,降至室温后,加入水分搅拌混合,通过制粒机进行制粒,获得软颗粒饲料,软颗粒饲料的粒径为10-15mm;
S4,将步骤S3中的软颗粒饲料进行低温烘干水分,烘干的温度26摄氏度,时间为48小时获得大鼠高尿酸血症模型饲料,所述大鼠高尿酸血症模型饲料中钙的含量为0.6%,磷的含量为0.9%。
表1为本实施例提供的大鼠高尿酸血症模型饲料的称量原料
重量 | 热量 | |
酪蛋白 | 200 | 800 |
DL-蛋氨酸 | 3 | 12 |
玉米淀粉 | 150 | 600 |
蔗糖 | 500 | 2000 |
纤维素 | 50 | 0 |
玉米油 | 50 | 450 |
复合矿物质 | 35 | 0 |
磷酸氢钙 | 2.71 | 0 |
磷酸二氢钾 | 19.24 | 0 |
腺嘌呤 | 1.54-2.05 | 0 |
复合维生素 | 10 | 40 |
酒石酸氢胆碱 | 2 | 0 |
合计 | 1023.49-1024 | 3902 |
本实施例还提供利用上述方法制备的大鼠高尿酸血症模型饲料。
wistar大鼠或SD大鼠共40只,周龄6周龄以下,体重150±20g,动物室为清洁级,室内温度控制在(25±2)℃之间,相对湿度为50%-70%,自然光照,避免噪音及其它干扰,自由进食和饮水。将大鼠随机均分为2组,即对照组和实施例组(模型组),连续饲喂14天,检测两组大鼠的血清尿酸(BUA)、肌酐(SCr)、尿素氮(BUN)浓度、血清氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)水平,观察大鼠尿液中尿肌酐(UCr)、尿素氮(UUN)、24h尿量(24h UV)、24h尿酸排泄量(24h UUA),和肝肾质量及系数。
如图2-4所示,实施例组大鼠血清尿酸、24h尿量、24h尿酸排泄量、血清肌酐、血清尿素氮、血清总胆固醇、血清甘油三酯、低血清密度脂蛋白均显著高于对照组大鼠,实施例组大鼠的尿液中尿肌酐和尿液尿素氮显著低于对照组的大鼠,说明实施例的大鼠构建高尿酸血症模型已经完成。实施例组的大鼠的肝肾质量及系数均高于对照组大鼠,说明实施例组的大鼠已经出现慢性肾功能损伤。此外实施例组的大鼠的SCr的数值只是达到250μmol/L,BUN数值只是达到40mmol/L,虽然均高于对照组大鼠,但是仍然为慢性肾功能障碍,并没有造成不可逆的肾脏严重器质性损伤,利用后续药物的改善和实验性研究。
上述仅本发明较佳可行实施例,并非是对本发明的限制,本发明也并不限于上述举例,本技术领域的技术人员,在本发明的实质范围内,所作出的变化、改型、添加或替换,也应属于本发明的保护范围。
Claims (7)
1.大鼠高尿酸血症模型饲料的制备方法,其特征在于,包括如下步骤:
S1,精确称取基础饲料、0.15%-0.2%质量比的腺嘌呤进行混合,获得混合粉料;
S2,步骤S1中的混合粉料加入玉米油进行搅拌,获得油料混合物;
S3,步骤S2中的油料混合物放置在冷却桶中进行降温处理后,加入水分搅拌混合,通过制粒机进行制粒,获得软颗粒饲料;
S4,将步骤S3中的软颗粒饲料进行低温烘干水分,获得大鼠高尿酸血症模型饲料,所述大鼠高尿酸血症模型饲料中钙的含量为0.6%,磷的含量为0.9%。
2.根据权利要求1所述的大鼠高尿酸血症模型饲料的制备方法,其特征在于,步骤S1中,所述基础饲料按质量百分比计包括19.57%酪蛋白、0.29%DL-蛋氨酸、14.68%玉米淀粉、48.93%蔗糖、4.89%纤维素、3.42%复合矿物质、0.27%磷酸氢钙、1.88%磷酸二氢钾、0.98%复合维生素和0.20%酒石酸氢胆碱。
3.根据权利要求1所述的大鼠高尿酸血症模型饲料的制备方法,其特征在于,步骤S2中,按质量比计,所述玉米油为4.89%。
4.根据权利要求1所述的大鼠高尿酸血症模型饲料的制备方法,其特征在于,步骤S3中,所述油料混合物放置在冷却桶中降至室温,所述软颗粒饲料的粒径为10-15mm。
5.根据权利要求1所述的大鼠高尿酸血症模型饲料的制备方法,其特征在于,步骤S4中,所述烘干的温度为26摄氏度,时间为48小时。
6.大鼠高尿酸血症模型饲料,其特征在于,根据权利要求1-5任一项所述的方法制备的大鼠高尿酸血症模型饲料。
7.大鼠高尿酸血症模型饲料的应用,用于构建大鼠高尿酸血症模型,其特征在于,连续给wistar大鼠或SD大鼠饲喂权利要求6所述的大鼠高尿酸血症模型饲料14-21天,自由饮水,饲喂后的大鼠血尿酸为正常饮食的大鼠血尿酸的3-4倍,即大鼠高尿酸血症模型构建完成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010885542.7A CN111772050A (zh) | 2020-08-28 | 2020-08-28 | 大鼠高尿酸血症模型饲料及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010885542.7A CN111772050A (zh) | 2020-08-28 | 2020-08-28 | 大鼠高尿酸血症模型饲料及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111772050A true CN111772050A (zh) | 2020-10-16 |
Family
ID=72762652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010885542.7A Pending CN111772050A (zh) | 2020-08-28 | 2020-08-28 | 大鼠高尿酸血症模型饲料及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111772050A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112401079A (zh) * | 2020-11-25 | 2021-02-26 | 常州鼠一鼠二生物科技有限公司 | 小鼠髓鞘脱失模型饲料及其制备方法和应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103125439A (zh) * | 2013-02-21 | 2013-06-05 | 李长贵 | 一种构建高尿酸血症合并糖尿病的动物模型的方法 |
CN103263445A (zh) * | 2013-05-20 | 2013-08-28 | 李长贵 | 一种构建高尿酸血症致肾间质纤维化的动物模型的方法 |
CN103385215A (zh) * | 2012-05-07 | 2013-11-13 | 浙江中医药大学 | 一种高嘌呤饲料喂养致生活性高血压动物模型的制备方法 |
CN106190953A (zh) * | 2016-07-25 | 2016-12-07 | 华南理工大学 | 一种高尿酸血症细胞模型及其构建方法与在降尿酸功效评价方面的应用 |
CN106234298A (zh) * | 2016-07-22 | 2016-12-21 | 浙江工商大学 | 一种短期内建立高脂血症大鼠模型的方法 |
US20170055504A1 (en) * | 2014-05-08 | 2017-03-02 | Phoenixbio Co., Ltd. | Hyperuricemia model |
CN106900652A (zh) * | 2017-03-16 | 2017-06-30 | 青岛大学 | 一种高尿酸血症模型的构建方法 |
JP2019033708A (ja) * | 2017-08-18 | 2019-03-07 | 学校法人帝京大学 | ヒト尿酸代謝モデル動物 |
-
2020
- 2020-08-28 CN CN202010885542.7A patent/CN111772050A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103385215A (zh) * | 2012-05-07 | 2013-11-13 | 浙江中医药大学 | 一种高嘌呤饲料喂养致生活性高血压动物模型的制备方法 |
CN103125439A (zh) * | 2013-02-21 | 2013-06-05 | 李长贵 | 一种构建高尿酸血症合并糖尿病的动物模型的方法 |
CN103263445A (zh) * | 2013-05-20 | 2013-08-28 | 李长贵 | 一种构建高尿酸血症致肾间质纤维化的动物模型的方法 |
US20170055504A1 (en) * | 2014-05-08 | 2017-03-02 | Phoenixbio Co., Ltd. | Hyperuricemia model |
CN106234298A (zh) * | 2016-07-22 | 2016-12-21 | 浙江工商大学 | 一种短期内建立高脂血症大鼠模型的方法 |
CN106190953A (zh) * | 2016-07-25 | 2016-12-07 | 华南理工大学 | 一种高尿酸血症细胞模型及其构建方法与在降尿酸功效评价方面的应用 |
CN106900652A (zh) * | 2017-03-16 | 2017-06-30 | 青岛大学 | 一种高尿酸血症模型的构建方法 |
JP2019033708A (ja) * | 2017-08-18 | 2019-03-07 | 学校法人帝京大学 | ヒト尿酸代謝モデル動物 |
Non-Patent Citations (1)
Title |
---|
王宗涛等: "高尿酸血症大鼠模型的实验研究", 《中华内分泌代谢杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112401079A (zh) * | 2020-11-25 | 2021-02-26 | 常州鼠一鼠二生物科技有限公司 | 小鼠髓鞘脱失模型饲料及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Niu et al. | Effect of curcumin on growth performance, inflammation, insulin level, and lipid metabolism in weaned piglets with IUGR | |
JP2018528785A (ja) | タンパク質が豊富なスラウストキトリッドのバイオマス、培養方法および使用 | |
CN102771673A (zh) | 一种构建代谢综合症动物模型的高脂纯化饲料及加工工艺 | |
CN106538869A (zh) | 一种乳猪饲料 | |
CN109170259A (zh) | 一种复合猪饲料及其制备方法 | |
CN111772050A (zh) | 大鼠高尿酸血症模型饲料及其制备方法和应用 | |
CN111513177A (zh) | 一种中草药发酵饲料的制备方法 | |
Zhang et al. | Effect of dietary compound acidifiers supplementation on growth performance, serum biochemical parameters, and body composition of juvenile American eel (Anguilla rostrata) | |
CN111728096B (zh) | 大鼠高脂血症模型饲料及其制备方法和应用 | |
CN111418714A (zh) | 用于缓解大口黑鲈肝糖原累积的配合饲料及其制备方法 | |
CN111494402B (zh) | 一种兽用复合维生素的片剂及其制备方法 | |
Zhao et al. | Ruminant lick blocks, particularly in China: A Review | |
CN106615888B (zh) | 一种影响嘌呤代谢的酵母果糖组合物 | |
CN106509491A (zh) | 一种大菱鲆配合饲料及其制备方法 | |
CN111297842A (zh) | ω脂肪酸在调节体内尿酸水平中的应用 | |
CN112841431A (zh) | 一种适合口服使用的奶牛酮病防治复合配方 | |
Jardstedt et al. | The effect of feeding roughages of varying digestibility prepartum on energy status and metabolic profiles in beef cows around parturition | |
CN111820319A (zh) | 一种提高卵形鲳鲹饲料糖利用率的酶及其应用 | |
CN116694530B (zh) | 一种乳杆菌组合物及其应用 | |
CN110408552A (zh) | 富硒酵母在制备朱砂引起的肝肾毒性的解毒药物中的应用 | |
CN114376983B (zh) | 一种适用于高尿酸人群的天然提取物复合颗粒剂 | |
CN108060098A (zh) | 一种大肠杆菌的发酵培养方法及其在饲料添加剂中的应用 | |
CN115192603B (zh) | 锂盐在制备防治奶牛酮病制剂中的应用 | |
CN108576474A (zh) | 提高蛋鸡鸡蛋品质的饲料添加剂 | |
CN112715774B (zh) | 一种雏禽饲料及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |